Oral Hyaluronic Acid Supplementation for the Treatment of Dry Eye Disease: A Pilot Study

Purpose. To evaluate the clinical efficacy of oral hyaluronic acid (HA) in patients with dry eye disease (DED). Study Design. Prospective randomized controlled trial. Methods. This trial enrolled 54 subjects and they were randomized into the study or control group. The inclusion criteria were as fol...

Full description

Saved in:
Bibliographic Details
Main Authors: Yeseul Kim, Chan Hee Moon, Bo-Yeon Kim, Sun Young Jang
Format: Article
Language:English
Published: Wiley 2019-01-01
Series:Journal of Ophthalmology
Online Access:http://dx.doi.org/10.1155/2019/5491626
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832558281177956352
author Yeseul Kim
Chan Hee Moon
Bo-Yeon Kim
Sun Young Jang
author_facet Yeseul Kim
Chan Hee Moon
Bo-Yeon Kim
Sun Young Jang
author_sort Yeseul Kim
collection DOAJ
description Purpose. To evaluate the clinical efficacy of oral hyaluronic acid (HA) in patients with dry eye disease (DED). Study Design. Prospective randomized controlled trial. Methods. This trial enrolled 54 subjects and they were randomized into the study or control group. The inclusion criteria were as follows: (1) >18 years of age; (2) distance best-corrected visual acuity ≥ 20/40 Snellen equivalent in each eye; (3) IOP ≤ 21 mmHg in both eyes; (4) ocular surface disease index (OSDI) score of ≥18 and <65; (5) <10 seconds of tear break up time (TBUT); (6) >5 corneal spots of corneal fluorescein staining (CFS); and (7) ≤ 10 mm/5 min of the Schirmer test. All subjects were treated with a topical HA, and the study group was supplemented with oral HA. OSDI, TBUT, CFS, and the Schirmer test were evaluated for ocular surface parameters. Results. 24 patients were assigned in the study group. Significant improvement of OSDI, TBUT, and CFS was observed at 1 month and 3 months after oral HA administration in the study group. At baseline and follow-up at 1 and 3 months, OSDI scores were 61.8 ± 16.2, 47.3 ± 11.6, and 42.3 ± 9.1, respectively (P<0.001). TBUT was improved after treatment for 1 month and 3 months (4.2 ± 1.1; P=0.005 and 4.7 ± 1.1; P<0.012). There were also statistically significant improvements in the CSF (1.8 ± 1.0, 0.8 ± 0.7; P<0.001) at baseline compared with those at 1 month. Conclusions. A combined supplement of both oral and topical HA more efficiently improves corneal epithelial wound healing and related symptoms than topical HA alone, in DED.
format Article
id doaj-art-e4cf46cd7cbd4914803fa092673455f3
institution Kabale University
issn 2090-004X
2090-0058
language English
publishDate 2019-01-01
publisher Wiley
record_format Article
series Journal of Ophthalmology
spelling doaj-art-e4cf46cd7cbd4914803fa092673455f32025-02-03T01:32:52ZengWileyJournal of Ophthalmology2090-004X2090-00582019-01-01201910.1155/2019/54916265491626Oral Hyaluronic Acid Supplementation for the Treatment of Dry Eye Disease: A Pilot StudyYeseul Kim0Chan Hee Moon1Bo-Yeon Kim2Sun Young Jang3Department of Ophthalmology, Soonchunhyang University Bucheon Hospital, Bucheon, Republic of KoreaEunpyeong Hopeful Eye Clinic, Seoul, Republic of KoreaDivision of Endocrinology and Metabolism, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Republic of KoreaDepartment of Ophthalmology, Soonchunhyang University Bucheon Hospital, Bucheon, Republic of KoreaPurpose. To evaluate the clinical efficacy of oral hyaluronic acid (HA) in patients with dry eye disease (DED). Study Design. Prospective randomized controlled trial. Methods. This trial enrolled 54 subjects and they were randomized into the study or control group. The inclusion criteria were as follows: (1) >18 years of age; (2) distance best-corrected visual acuity ≥ 20/40 Snellen equivalent in each eye; (3) IOP ≤ 21 mmHg in both eyes; (4) ocular surface disease index (OSDI) score of ≥18 and <65; (5) <10 seconds of tear break up time (TBUT); (6) >5 corneal spots of corneal fluorescein staining (CFS); and (7) ≤ 10 mm/5 min of the Schirmer test. All subjects were treated with a topical HA, and the study group was supplemented with oral HA. OSDI, TBUT, CFS, and the Schirmer test were evaluated for ocular surface parameters. Results. 24 patients were assigned in the study group. Significant improvement of OSDI, TBUT, and CFS was observed at 1 month and 3 months after oral HA administration in the study group. At baseline and follow-up at 1 and 3 months, OSDI scores were 61.8 ± 16.2, 47.3 ± 11.6, and 42.3 ± 9.1, respectively (P<0.001). TBUT was improved after treatment for 1 month and 3 months (4.2 ± 1.1; P=0.005 and 4.7 ± 1.1; P<0.012). There were also statistically significant improvements in the CSF (1.8 ± 1.0, 0.8 ± 0.7; P<0.001) at baseline compared with those at 1 month. Conclusions. A combined supplement of both oral and topical HA more efficiently improves corneal epithelial wound healing and related symptoms than topical HA alone, in DED.http://dx.doi.org/10.1155/2019/5491626
spellingShingle Yeseul Kim
Chan Hee Moon
Bo-Yeon Kim
Sun Young Jang
Oral Hyaluronic Acid Supplementation for the Treatment of Dry Eye Disease: A Pilot Study
Journal of Ophthalmology
title Oral Hyaluronic Acid Supplementation for the Treatment of Dry Eye Disease: A Pilot Study
title_full Oral Hyaluronic Acid Supplementation for the Treatment of Dry Eye Disease: A Pilot Study
title_fullStr Oral Hyaluronic Acid Supplementation for the Treatment of Dry Eye Disease: A Pilot Study
title_full_unstemmed Oral Hyaluronic Acid Supplementation for the Treatment of Dry Eye Disease: A Pilot Study
title_short Oral Hyaluronic Acid Supplementation for the Treatment of Dry Eye Disease: A Pilot Study
title_sort oral hyaluronic acid supplementation for the treatment of dry eye disease a pilot study
url http://dx.doi.org/10.1155/2019/5491626
work_keys_str_mv AT yeseulkim oralhyaluronicacidsupplementationforthetreatmentofdryeyediseaseapilotstudy
AT chanheemoon oralhyaluronicacidsupplementationforthetreatmentofdryeyediseaseapilotstudy
AT boyeonkim oralhyaluronicacidsupplementationforthetreatmentofdryeyediseaseapilotstudy
AT sunyoungjang oralhyaluronicacidsupplementationforthetreatmentofdryeyediseaseapilotstudy